AIMS: Atrial fibrillation (AF) is a frequent co-morbidity in heart failure (HF) associated with increased mortality, but little is known about the mechanisms underlying AF onset in HF patients. We evaluated the association of cardiovascular and genetic risk factors with AF in HF patients. METHODS AND RESULTS: Individuals hospitalized for HF (n = 1040; 500 with AF) were identified from a large, population-based cohort study (n = 30 447; 2339 with AF). Genetic polymorphisms in the chromosomal regions 4q25 (rs2200733) and 16q22 (rs2106261) associated with AF in genome-wide association studies were genotyped. Association of cardiovascular risk factors and polymorphisms with AF was tested in HF patients and the entire cohort using both prospective and non-time-dependent models. Cardiovascular risk factors-hypertension, body mass index, sex, smoking, diabetes, and myocardial infarction-were associated with AF in the entire cohort but not in HF patients. In contrast, polymorphisms on chromosomes 16q22 and 4q25 were associated with AF both in the entire cohort and in HF patients, conferring 75% [95% confidence interval (CI) 35-126, P = 2 × 10(-5)] and 57% (95% CI 18-109, P = 0.002) increased risk of AF per copy in HF patients, respectively. In the entire cohort, AF risk in the presence of HF was multiplicatively magnified by genotype for 16q22 (P for interaction = 7 × 10(-4)) but not 4q25 (P = 0.83). In prospective analyses excluding patients with AF diagnosis prior to or simultaneously with HF diagnosis, 16q22 but not 4q25 remained robustly associated with AF (hazard ratio 1.96, 95% CI 1.40-2.73, P = 8 × 10(-5)). The proportion of AF diagnoses in HF patients attributable to polymorphisms was 19% and 12%, respectively. CONCLUSIONS: A polymorphism in the ZFHX3 gene, encoding a cardiac transcription factor, was associated with increased AF risk in HF patients, and the genetic association with AF was more pronounced in HF patients than in the general population.
AIMS: Atrial fibrillation (AF) is a frequent co-morbidity in heart failure (HF) associated with increased mortality, but little is known about the mechanisms underlying AF onset in HF patients. We evaluated the association of cardiovascular and genetic risk factors with AF in HF patients. METHODS AND RESULTS: Individuals hospitalized for HF (n = 1040; 500 with AF) were identified from a large, population-based cohort study (n = 30 447; 2339 with AF). Genetic polymorphisms in the chromosomal regions 4q25 (rs2200733) and 16q22 (rs2106261) associated with AF in genome-wide association studies were genotyped. Association of cardiovascular risk factors and polymorphisms with AF was tested in HF patients and the entire cohort using both prospective and non-time-dependent models. Cardiovascular risk factors-hypertension, body mass index, sex, smoking, diabetes, and myocardial infarction-were associated with AF in the entire cohort but not in HF patients. In contrast, polymorphisms on chromosomes 16q22 and 4q25 were associated with AF both in the entire cohort and in HF patients, conferring 75% [95% confidence interval (CI) 35-126, P = 2 × 10(-5)] and 57% (95% CI 18-109, P = 0.002) increased risk of AF per copy in HF patients, respectively. In the entire cohort, AF risk in the presence of HF was multiplicatively magnified by genotype for 16q22 (P for interaction = 7 × 10(-4)) but not 4q25 (P = 0.83). In prospective analyses excluding patients with AF diagnosis prior to or simultaneously with HF diagnosis, 16q22 but not 4q25 remained robustly associated with AF (hazard ratio 1.96, 95% CI 1.40-2.73, P = 8 × 10(-5)). The proportion of AF diagnoses in HF patients attributable to polymorphisms was 19% and 12%, respectively. CONCLUSIONS: A polymorphism in the ZFHX3 gene, encoding a cardiac transcription factor, was associated with increased AF risk in HF patients, and the genetic association with AF was more pronounced in HF patients than in the general population.
Authors: M Haïssaguerre; P Jaïs; D C Shah; A Takahashi; M Hocini; G Quiniou; S Garrigue; A Le Mouroux; P Le Métayer; J Clémenty Journal: N Engl J Med Date: 1998-09-03 Impact factor: 91.245
Authors: Denise Hilfiker-Kleiner; Andres Hilfiker; Martin Fuchs; Karol Kaminski; Arnd Schaefer; Bernhard Schieffer; Anja Hillmer; Andreas Schmiedl; Zhaoping Ding; Edith Podewski; Eva Podewski; Valeria Poli; Michael D Schneider; Rainer Schulz; Joon-Keun Park; Kai C Wollert; Helmut Drexler Journal: Circ Res Date: 2004-06-10 Impact factor: 17.367
Authors: Thomas J Wang; Martin G Larson; Daniel Levy; Ramachandran S Vasan; Eric P Leip; Philip A Wolf; Ralph B D'Agostino; Joanne M Murabito; William B Kannel; Emelia J Benjamin Journal: Circulation Date: 2003-05-27 Impact factor: 29.690
Authors: Marguerite R Irvin; Degui Zhi; Stella Aslibekyan; Steven A Claas; Devin M Absher; Jose M Ordovas; Hemant K Tiwari; Steve Watkins; Donna K Arnett Journal: PLoS One Date: 2014-06-06 Impact factor: 3.240
Authors: Mariëlle Kloosterman; Bernadet T Santema; Carolina Roselli; Christopher P Nelson; Andrea Koekemoer; Simon P R Romaine; Isabelle C Van Gelder; Carolyn S P Lam; Vicente A Artola; Chim C Lang; Leon L Ng; Marco Metra; Stefan Anker; Gerasimos Filippatos; Kenneth Dickstein; Piotr Ponikowski; Pim van der Harst; Peter van der Meer; Dirk J van Veldhuisen; Emelia J Benjamin; Adriaan A Voors; Nilesh J Samani; Michiel Rienstra Journal: Eur J Heart Fail Date: 2020-01-09 Impact factor: 15.534
Authors: Anna Egerstedt; John Berntsson; Maya Landenhed Smith; Olof Gidlöf; Roland Nilsson; Mark Benson; Quinn S Wells; Selvi Celik; Carl Lejonberg; Laurie Farrell; Sumita Sinha; Dongxiao Shen; Jakob Lundgren; Göran Rådegran; Debby Ngo; Gunnar Engström; Qiong Yang; Thomas J Wang; Robert E Gerszten; J Gustav Smith Journal: Nat Commun Date: 2019-12-20 Impact factor: 14.919